|Net Assets||1.29 Bil|
|Morningstar Risk||Above Average|
- Last NAV update 4/17/2014 4:00 PM ET
|The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. It predominantly invests in equity securities, primarily common stock. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of foreign or U.S. issuer. It is non-diversified.|
- Year to date performance as of 4/17/2014 12:00 AM ET
|Fund Family||Franklin Templeton Investments|
|Fund Manager||Evan McCulloch|
|Minimum Initial Purchase||1,000.00|
|Minimum IRA Investment||250.00|
- * Annualized returns
- Performance as of 4/17/2014 12:00 AM ET
|Net Assets||1.29 Bil||711.24 Mil|
|Avg Market Cap||9.39 Bil||31.69 Bil|
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.